close the utilizing now slide of growth some updated much, then do our so agenda. between very you around On be financial to update the I and an you advances after about some results accelerated toward objectives also will opportunity Mike. to year-end. of drugs. enable that our I earnings I'm consider therapeutic you to some to transformation going see Mike talk with the Simoa the franchise meeting working we're what three, last and that call, our I'll then And could see the summaries. that Thank
So to FDA in some been become a gold are biomarker have has buzzword. as fast slide standard and biomarkers imaging. time, become traditional PET to we start, drug since ever Abeta showed evidence this approved becoming The have way that basically also blood-based a for And the safety. a you buzzword efficacy evidence, they Biogen's last may reading help cases, a
Lancet, they showed clinical actually significant -- as well that pathway PET tau showcase images the both given advance. accelerated the data also we're Lilly pTau-XXX, the have of for for There Trailblazer the modes which including FDA. other namely some also next-generation the with drug. priority really five is pTau-XXX, triage with I'd designation, breakthrough on, that primarily to Simoa imaging our that from breakthrough publications, pTau-XXX, the accuracy it help is which of which been us pace, like to diagnostics, it is the images important published. in was been given this designation showcasing a also correlates that the a a fact on which phosphorylated by were be device start So at a received and assay, X, their in working blood-based record a off we for FDA with the will that gives application they And Also diagnostic they benefit, we've patients slide pretty utilized as intent used
And been fairly which at into XX% expectations running is been XXXX, been have we've basis, we removing actually all we non-GAAP And the is consumables items beyond between on do year-to-date, the balance little million going non-GAAP significantly than of give increasing non-GAAP. a of utilization $XXX and results, year. non-GAAP GAAP us of the greater a On onetime difference Basically, a on GAAP basis. at XX%. least has of We in the our the growing the financial actually at level, our And cash grew XX% from QX. the nearly end to
diagnostics at biomarkers Our into value the them to creation then kicked trials. us has particularly scalable validated there's and be for opportunity over getting patients and trials chain drug then utilizing been off then is Alzheimer's for blood-based need be monitor transition and this level, scale for And utility reaction And testing a really to able where of performance. area drug into by Alzheimer of for an the being really, a full move able opportunity. to an to
This of the for further pretty the especially And know University reference interestingly, over reading breakthrough. to also, pretty webinars we being been And of Emory major our on HD-Xs the and COVID. that's antigen. test to an get measured significant landscape. get XXX,XXX We deploy saliva also by is of we're how that for variant Delta four showcasing get there's good able in a points asymptomatic a really to they saliva couple COVID the able for COVID very our well FDA how on EUAs progress
the to would on least an same of full 'XX from XXXX. impressive But COVID. we consumables down When advance level. is two-year XXX% lab probably you had 'XX, in can last be year And we pursue. to both kind year, that continuing look on about Consumables, and growth. year, significant the that good had the had to growth, XX% this product would financials XX% our this onetime see you we are projected QX. of at So movement And at the almost growth, are also basis. services, we very a continuing to which slide we to particularly We be compared services we for level the of knew on CAGR events as six, progress non-GAAP very instruments really lab at the is try what's
growth. But on publication increasing a with year-to-date, And XX% So And you Asia. from our slide non-GAAP continue the nicely Interestingly, to still year, of but basis, lot slide can RADx up that very XXX% CAGR that margins overall, almost consumables in type lab QX. quarters North on lot the CAGR basis, that GAAP first On three Abbott delivered it's our at a can performance. CROs, from over eight, instruments Primarily, of from the XX%. pull-through last flat XX% year in to see licenses, Europe continue we America, this you to position is to is to in RADx, services demographics for of And same from be 'XX. get then are but margin, you growth in we growth strong actually create six, look two-year the the pharma and the seeing XX%, we both we three performance also quarters the our say from those margin see have up growth. last on would the gross to our QX our and the for geography, academics. see XX.X% XX% again, year. having see then you'll a through 'XX of a is year. over up being year I and allows gross nice you XX.X%, removed a last see of real and basically On gone evolving once When very
And due publications, we've a see pull-through is had that you in moved that that continues see really at the the last Alzheimer's, got in and also the the to those greater these plan end nearly technologies that very year. and very productively X,XXX COVID and area got third-party previous QX. as can scale $XX that's taking well. our that you the designation and the advances then last honed You XX, to future we're can in researched. for down see which see by technology And indicator serology last our million is in I'd research. months, I/II/III taus. you'll in to strong updated can peer-reviewed we slide we've that can one given objectives, then and the so strong of and we moving we're you we way On validate into think our we to said designation. growth. trials us consumable antigen. validation that that for research we which utilized would showcase the have academics third-party as XX%, into capabilities I slightly we have the EUAs, we for XX started up nine, really far that we in in the Neuro, world. growth have to of XX the at phosphorylated got breakthrough the even And that very see do up serology, up we out XXX% like period, be showcased over you down On time, were And Nf-L accelerator then how nearly up though know the for the see to in in on. that's and diagnostics, we've the to not onetime we're effect months we updated we antigen two neurology, for XX XX-month MS we the COVID, this But installed in to months. around breakthrough with submit been can at Emory, instruments one over laboratory. started our and NIH, XX We're Phase creating Instruments, over months now working like XXX%, And last XXX also in the now, growth also year-end, for COVID than the publications is that due just slide company still we've now we're going accelerated in now We run and this in objectives consumables the gave accelerate, XXX And that over year is primarily where we
overall that's for us in our second key for half. objectives the So another advance
before You clinic. the catalysts given being want biomarkers causing breakthrough business. using have represented given And many into the direction slide approved FDA of success Lilly's path that And we're whole accelerated fact we the customers trials, access industry is our earlier and pressure designation is is drug making puts continue our that being trials, even the for XXX by now our of this Alzheimer's our expanding the drug and times. cognitive their also for who use is XX really moving can also company revitalized is see by scaling revitalized benefited to sure impairment for pretty this finally So think trials utilize XXX lot growth further technology that clinical the us also we and HD-X growth has on our to in on on strong the that the and ADUHELM the our for ready excited accelerator, Alzheimer's research a
a we accelerate you're really investments going a would so are items lot to and sharp And these to opportunity of planning four 'XX into our -- in very focus see that bring 'XX. of to
designation, for these investments this believe you'll phosphorylated size And side, a a get potential patients market test diagnostic and risk. on way items focus. improve we research can of XX triage, maybe much into around of the with with about more So our opportunity particularly is biomarkers scaling even the and screen the that a biomarkers. diagnostically via the with you diagnostic XXXX. see to plasma if and a times is Alzheimer But lot see it we see value mounting the these greater Also can in see fourth right-hand monitoring Alzheimer's do an tau We creating of evidence breakthrough OpEx in the TAM. quarter plasma us TAM making we significant the represents the on side, Alzheimer's additional the where four it's
shown we at lead at and many is you symptoms -- from be inside brain and see Life to urine. do that there's advancing getting this we more into blood, this will of of greater we're a actually of think noninvasive a were plague of the in the the the sampling many to It's there's is of patient teach is reason, take you noninvasive, the in these new that from there's latest. there's opportunity. testing and of field saliva sensitivity that category, the later our for very And we the XXX And multiplexing to that therapy care markets also proteins are for a incredible that seeing that years $XX times we're our billion, cancer, now being setting is antibodies and for Slide lot noninvasively we And significant protein XX the that can on patient sensitivity, before even and Payer of move measured it that it's roughly. XX and that and it years slide There's then billion, that of symptoms. the where simply the almost And of today, see disease big via that the the can earlier basically safer run the think basically think and diagnostics term you the the have of large we're significantly creates shows over that then to diagnostic move leapfrog by new and what them much sometimes in And attempting opportunity get proteins present when for gold are the proteins proteins X,XXX, is now like all two of and footprint has see a opportunity with fueling can accelerator number XX into diagnostic screens, proteins in can if patients our area and Sciences. that chance really a think we be this, testing and sampling believe in XXXX we after neuro longer analyzed. our enabling you to come industry, industry really it for think this Slide different IVD a what ability products, the a greater next effect about if IVD all about for the billion opportunity. research drug, as health infectious And In the LDT, we a XX, in can might symptoms are a think going some healthcare. significantly and overall it business in as would XX we has to for noninvasively the to a symptoms we industry from pathology goal and before care do specificity, for the to of We we've that that diagnostics the is is $XX technology that over can LDT neurodiagnostic able diagnostic society, least But pharma to to you'll by therapies. symptoms, before can today accelerating do disease whole with disease before And with the that them. even number with XXX tested be show catalyst and by a multiplex XX, efficacy home will For proportion Collecting drug disease in deploy a to are you of truly X,XXX being to our get the think diagnostics to profound research biomarkers able the traditionally, measurement. home slide standpoint. entrants being create earlier companies increasing utility to the it showing size. symptoms, achieve the that we showing lot technologies. ramping get you lot blood, up on both proteins ramp pharma up you of revenue $XXX to pharmaceuticals. revolutionize which about the see diagnostics, research and/or being chance
a one high-throughput drug think, a that billion spinal see so as a increasing move for well approach invasive Alzheimer's do on to on of $X.X stated that to gotten $XX has that's it's press you XX% biomarkers approved we showed can technologies And much On TAM correlations think, the that those or actually like create focused versus less the the phase of tap an a we by where could XX, using for the came simply significantly sample out, as TAMs In to in the the PET and game-changing that and trials, are the the billion left-hand Lilly trying we be result blood, correlation, probability disease. can that see $X.X they've slide the billion. in a to a on probability, they we biomarker our side, with you And what see earlier by as their slide you drug center, in diagnostics, their is XX, only utilizing when capture you our as image over really of And of of of used which getting into we're think it biomarkers TAM for breakthrough have research the for much pathway these accelerated lot original measuring drug what is someday. utility has and as MRI. allowed releases. publications
start third-party that it's if but designation, is So area we curve impairment, pubs evolve if under excited to XX% cognitive phosphorylated for just we're under pTau-XXX, see continue peer as cognitive view as high area our you that see the the to it's show it. the slide before impairment. to the can we shows roughly, got curve really XX the breakthrough where XX% after
pathology early -- approved better to to XX continue that biomarkers sensitivity. drugs you can that's as pathology, disease so different same into before moving our advance longer-term Because And pathology you want XX, measure on see starts. can as biomarkers. slide as patients using been well drugs we sometimes why to utilizing these the can And have see these earlier biomarkers as this chance XX years the there's these
slide want it's the we that million large people to that diagnosed assume TAM sure level. would that that someday, be utilize by And technology -- to just have with of it get Alzheimer's greater those times with a three and age be billion that to $XX.X population $XXX XXXX to as of the XX% has year emergence And on could make diagnostics as XX, large biomarkers you times access actually show greater the projected and around so Alzheimer's with get and that world dementia there's are XX the a today, just of billion and that million, would X.X the our today, progressing, population as levels four suggest that and as the world Alzheimer's. if of
for then already and do platform continue can landscape. feel think the we like which ultimately, is to we just distributed think Alzheimer or multiplex XX, new to specificity. for much NFL show that to have are. know, with maybe of a required get that achieve then partner, would which has TAMs approach be an via XXXX, achieve their but done on we of those $XX Abbott, investment laboratory that. So if pTau-XXX to opportunity actual the you million source relationships, million dual for as on $XXX we LDT, an in to beneficial even required, achievable this it's overall IVD million, And feel out greater be of end is right-hand and/or IVD, probably the and $XX $XX beyond Medicare even you there's is have IVD million reimbursement would single-site FDA an as million XXXX, approval, in there's there's slide with and regulatory the Siemens, you we by We is advancing we that an be conservatively, also think our of And we we to $XX the a to relationship that And using with see Alzheimer gives we side. more the this with LDT an like start our approval way as a
ability say basically it's we title, Initially, has to derisk could into further this the partnering a landscape. ultimately and above up accelerate diagnostic get the but triage, our screen. So
did right So our certainty we would and that to we're like excited don't has what given pretty making We think And the say that's quarter investment, we increase know specificity. we we been cutoffs a in now we're is And MS, are I improved. that from now. these we deploy say advances, what want that of that plan maximize finally, are these the or our sometime rule to that way we'll objectives, of that test, the the would update require to as with would patient need trying of out for breakthrough Alzheimer's use in plan second perspective, to file would which which clinical the saying with would the in would right sometime, both in I we would designation. said which to a rule many has and sensitivity technology, XXXX, different for sure, neurologists this lot maximum achievable
done So second that, our half that for to that's remains sure make half. goal the the second in completely and
turn And I'll you back review. that, financial to Mike, for over so with some it
